2.9 Composite Materials

Oller, Sergio; Aramayo, Sergio A. Oller; Nallim, Liz G.; Martı́nez, Xavier

doi:10.1016/b978-0-12-809597-3.00220-0

Cited by 4 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar with the ππ, πK or ρρ puzzles discussed in Refs. [84,[95][96][97][98][99][100][101][102], the B → πρ puzzle has been noticed by some groups [103][104][105][106][107][108][109]. For example, in Ref.…”

Section: Numerical Results and Discussionmentioning

confidence: 99%

Quasi-two-body decays B(s)→Pρ→Pππ in the perturbative QCD approach

Xiao

et al. 2017

Phys. Rev. D

View full text Add to dashboard Cite

In this work, we calculate the CP -averaged branching ratios and the direct CP -violating asymmetries of the quasi-two-body decays B (s) → P (ρ →)ππ by employing the perturbative QCD (PQCD) approach (here P stands for a light pseudoscalar meson π, K, η or η ′ ). The vector current timelike form factor Fπ, which contains the final-state interactions between the pion pair in the resonant region associated with the P -wave states ρ(770) along with the two-pion distribution amplitudes, is employed to describe the interactions between the ρ and the pion pair under the hypothesis of the conserved vector current. We found that (a) the PQCD predictions for the branching ratios and the direct CP -violating asymmetries for most considered B (s) → P (ρ →)ππ decays agree with currently available data within errors, (b) for B(B → π 0 ρ 0 → π 0 (π + π − ), the PQCD prediction is much smaller than the measured one, and (c) for the B + → π + (ρ 0 →)π + π − decay mode, there is a negative CP asymmetry (−27.5 +3.0 −3.7 )%, which agrees with other theoretical predictions but is different in sign from those reported by BABAR and LHCb Collaborations.

show abstract

Section: Numerical Results and Discussionmentioning

confidence: 99%

Quasi-two-body decays B(s)→Pρ→Pππ in the perturbative QCD approach

Xiao

et al. 2017

Phys. Rev. D

View full text Add to dashboard Cite

show abstract

“…Thanks to the high scaffold customisation potential (NP or functionalised matrix for a gradual drug release), we can design and bioprint 5D personalised medical devices. In detail, modifying the composite biomaterial [42][43][44][45] and the manufacturing methods, the interaction 45,46 of the transplanted structures with the biological substrate can be varied accordingly to experimental needs. When it is possible to graft biocompatible objects (prosthesis, STENT, etc.)…”

Section: Discussionmentioning

confidence: 99%

In-vivo vascular application via ultra-fast bioprinting for future 5D personalised nanomedicine

Foresti

Rossi

Pinelli

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The design of 3D complex structures enables new correlation studies between the engineering parameters and the biological activity. Moreover, additive manufacturing technology could revolutionise the personalised medical pre-operative management due to its possibility to interplay with computer tomography. Here we present a method based on rapid freeze prototyping (RFP) 3D printer, reconstruction cutting, nano dry formulation, fast freeze gelation, disinfection and partial processes for the 5D digital models functionalisation. We elaborated the high-resolution computer tomography scan derived from a complex human peripheral artery and we reconstructed the 3D model of the vessel in order to obtain and verify the additive manufacturing processes. Then, based on the drug-eluting balloon selected for the percutaneous intervention, we reconstructed the biocompatible eluting-freeform coating containing 40 nm fluorescent nanoparticles (NPs) by means of RFP printer and we tested the in-vivo feasibility. We introduced the NPs-loaded 5D device in a rat's vena cava. The coating dissolved in a few minutes releasing NPs which were rapidly absorbed in vascular smooth muscle cell (VSMC) and human umbilical vein endothelial cell (HUVEC) in-vitro. We developed 5D highresolution self-dissolving devices incorporating NPs with the perspective to apply this method to the personalised medicine.Chronic lower extremity peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis, and one of the main causes in loss of walking ability. Two treatments for lower extremity PAD are currently available: surgical (primarily bypass surgery) and endovascular treatment (EVT) mainly through balloon angioplasty. In fact, due to its clear advantages at least in the short-term, EVT represents -at present -the most common treatment for PAD 1 . Drug-Coated Balloons are made up of a semi-compliant or non-compliant balloon catheter covered with an anti-proliferative agent (typically paclitaxel), and an excipient (e.g. urea) to facilitate drug transfer into the vessel wall after balloon inflation 2 . The BASIL (Bypass Versus Angioplasty for Severe Ischemia of the Leg) trial is the only multicentre, randomised and controlled trial (RCT) which compared these two treatments 3 . One of the major limitations of this RCT is that current endovascular technologies have not been included 4 . Important advances developed in endovascular technologies address a great variety of anatomic challenges, while current and future efforts are directed towards improving long-term patency rates.The 3D printing techniques demonstrate the high potentiality of interactive processes applied to medicine and associated toxicity/vitality studies 5,6 . Materials selected for bio-printed scaffolds are predominantly based on both naturally derived polymers (including gelatine, collagen, alginate, chitosan and hyaluronic acid) or synthetic molecules (polyethylene glycol) 7-9 , allowing precise control 10 of chemical and physical properties 11 .

show abstract